Base de dados : MEDLINE
Pesquisa : C04.557.470.200.025.075 [Categoria DeCS]
Referências encontradas : 8555 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 856 ir para página                         

  1 / 8555 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449064
[Au] Autor:Hou Y; Tozbikian G; Zynger DL; Li Z
[Ad] Endereço:From the Department of Pathology, The Ohio State University Wexner Medical Center, Columbus.
[Ti] Título:Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
[So] Source:Am J Clin Pathol;147(6):541-548, 2017 Jun 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX. Methods: Magee equation RS was calculated in 438 cases and correlated with Oncotype DX RS. Results: The Pearson correlation coefficient ( r ) for the Magee equation and Oncotype DX RS was 0.6645 ( P < .00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively. Conclusions: The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/diagnóstico
Adenocarcinoma/diagnóstico
Biomarcadores Tumorais/genética
Neoplasias da Mama/diagnóstico
Carcinoma Ductal de Mama/diagnóstico
Carcinoma Lobular/diagnóstico
[Mh] Termos MeSH secundário: Adenocarcinoma/genética
Adenocarcinoma/patologia
Adenocarcinoma Mucinoso/genética
Adenocarcinoma Mucinoso/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/genética
Neoplasias da Mama/patologia
Carcinoma Ductal de Mama/genética
Carcinoma Ductal de Mama/patologia
Carcinoma Lobular/genética
Carcinoma Lobular/patologia
Feminino
Genômica
Seres Humanos
Meia-Idade
Técnicas de Diagnóstico Molecular/métodos
Medição de Risco
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx008


  2 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29267283
[Au] Autor:Milewski D; Balli D; Ustiyan V; Le T; Dienemann H; Warth A; Breuhahn K; Whitsett JA; Kalinichenko VV; Kalin TV
[Ad] Endereço:Division of Pulmonary Biology, the Perinatal Institute of Cincinnati Children's Research Foundation, Cincinnati, Ohio, United States of America.
[Ti] Título:FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas.
[So] Source:PLoS Genet;13(12):e1007097, 2017 12.
[Is] ISSN:1553-7404
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lung cancer remains one of the most prominent public health challenges, accounting for the highest incidence and mortality among all human cancers. While pulmonary invasive mucinous adenocarcinoma (PIMA) is one of the most aggressive types of non-small cell lung cancer, transcriptional drivers of PIMA remain poorly understood. In the present study, we found that Forkhead box M1 transcription factor (FOXM1) is highly expressed in human PIMAs and associated with increased extracellular mucin deposition and the loss of NKX2.1. To examine consequences of FOXM1 expression in tumor cells in vivo, we employed an inducible, transgenic mouse model to express an activated FOXM1 transcript in urethane-induced benign lung adenomas. FOXM1 accelerated tumor growth, induced progression from benign adenomas to invasive, metastatic adenocarcinomas, and induced SOX2, a marker of poorly differentiated tumor cells. Adenocarcinomas in FOXM1 transgenic mice expressed increased MUC5B and MUC5AC, and reduced NKX2.1, which are characteristics of mucinous adenocarcinomas. Expression of FOXM1 in KrasG12D transgenic mice increased the mucinous phenotype in KrasG12D-driven lung tumors. Anterior Gradient 2 (AGR2), an oncogene critical for intracellular processing and packaging of mucins, was increased in mouse and human PIMAs and was associated with FOXM1. FOXM1 directly bound to and transcriptionally activated human AGR2 gene promoter via the -257/-247 bp region. Finally, using orthotopic xenografts we demonstrated that inhibition of either FOXM1 or AGR2 in human PIMAs inhibited mucinous characteristics, and reduced tumor growth and invasion. Altogether, FOXM1 is necessary and sufficient to induce mucinous phenotypes in lung tumor cells in vivo.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/patologia
Adenocarcinoma/metabolismo
Adenocarcinoma/patologia
Adenoma/patologia
Proteína Forkhead Box M1/metabolismo
Neoplasias Pulmonares/metabolismo
Neoplasias Pulmonares/patologia
Proteínas/metabolismo
[Mh] Termos MeSH secundário: Células A549
Adenocarcinoma/genética
Adenocarcinoma Mucinoso/genética
Adenocarcinoma Mucinoso/metabolismo
Adenoma/genética
Adenoma/metabolismo
Animais
Carcinoma Pulmonar de Células não Pequenas/genética
Carcinoma Pulmonar de Células não Pequenas/metabolismo
Carcinoma Pulmonar de Células não Pequenas/patologia
Linhagem Celular Tumoral
Progressão da Doença
Proteína Forkhead Box M1/genética
Xenoenxertos
Seres Humanos
Neoplasias Pulmonares/genética
Masculino
Camundongos
Camundongos Endogâmicos NOD
Camundongos Transgênicos
Regiões Promotoras Genéticas
Proteínas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (FOXM1 protein, human); 0 (Forkhead Box Protein M1); 0 (Proteins); EC 5.3.4.1 (AGR2 protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180303
[Lr] Data última revisão:
180303
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pgen.1007097


  3 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27770344
[Au] Autor:Sugarbaker PH
[Ad] Endereço:Program in Peritoneal Surface Oncology, Center for Gastrointestinal Malignancy, MedStar Washington Hospital Center, Washington, DC, USA. paul.sugarbaker@medstar.net.
[Ti] Título:When and When Not to Perform a Right Colon Resection with Mucinous Appendiceal Neoplasms.
[So] Source:Ann Surg Oncol;24(3):729-732, 2017 Mar.
[Is] ISSN:1534-4681
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mucinous appendiceal neoplasms (MAN) with peritoneal dissemination is treated as a standard of care using cytoreductive surgery and hyperthermic perioperative chemotherapy. The extent of the resection of peritoneal surfaces and visceral structures is generally well defined. Exception to this consensus regarding structures to be removed are the right colon and adjacent ileocolic lymph nodes. METHODS: From a prospectively maintained database, all patients with a histologic diagnosis of peritoneal mucinous carcinoma (PMCA) who underwent complete cytoreductive surgery were assessed for the presence versus absence of adenocarcinoma in lymph nodes within the appendiceal mesentery and/or in the lymph nodes of the ileocolic group. The histologic grade of the PMCA was correlated with the incidence of lymph node invasion. Also, in those PMCA patients who had no evidence of lymph node invasion, recurrence within the ileocolic lymph nodes was determined by computed tomography or second look. RESULTS: In a database of MAN patients, 299 had a histologic diagnosis of PMCA. In well-differentiated (n = 44), moderately differentiated (n = 107), and poorly differentiated (n = 148) PMCA specimens, there were 6.8, 5.6, and 29 % positive lymph nodes, respectively. None of these 151 patients with well- or moderately differentiated PMCA had a computed tomographic scan or clinical evidence by second-look surgery of recurrence within the ileocolic lymph nodes. CONCLUSIONS: There is a low incidence (6.0 %) of positive lymph nodes in patients with low or moderately differentiated PMCA. With high-grade disease, lymph node invasion increased to 29.0 %. Right colectomy is indicated in patients with high-grade PMCA.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/secundário
Adenocarcinoma Mucinoso/cirurgia
Neoplasias do Apêndice/patologia
Neoplasias do Apêndice/cirurgia
Colectomia
Seleção de Pacientes
[Mh] Termos MeSH secundário: Colo Ascendente/cirurgia
Colo Transverso/cirurgia
Seres Humanos
Íleo
Linfonodos/diagnóstico por imagem
Linfonodos/patologia
Metástase Linfática
Gradação de Tumores
Estudos Retrospectivos
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE
[do] DOI:10.1245/s10434-016-5632-2


  4 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443760
[Au] Autor:Fritz S; Küper-Steffen R; Feilhauer K; Sommer CM; Richter GM; Hennig R; Köninger J
[Ti] Título:Resection of benign side-branch intraductal papillary mucinous neoplasm of the pancreas-is long term follow-up indicated?: A case report and review of the literature.
[So] Source:Medicine (Baltimore);97(7):e9894, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Intraductal papillary mucinous neoplasms of the pancreas (IPMNs) are benign cystic tumors with a relevant risk of malignant transformation over time. Currently, follow-up after surgical resection of benign IPMNs remains controversial. PATIENT CONCERNS: This is a case report of a 68-year-old male who underwent pancreatic head resection for a multicystic side-branch IPMN with low-grade epithelial dysplasia in March 2009 at the Katharinenhospital Stuttgart, Germany. DIAGNOSES: During postoperative follow-up, a new solid, slightly hypodense lesion in the tail of the pancreas measuring 2.4 cm in diameter was diagnosed in July 2016. Preoperative staging revealed no signs of distant metastasis. INTERVENTION: Subsequently, the patient underwent pancreatic tail resection including splenectomy. Histology revealed IPMN-associated adenocarcinoma of the pancreas pT3, pN1 (2/24), M0, R0. OUTCOMES: Patients with IPMN bare a relatively high overall risk of developing pancreatic cancer. The 5-year incidence has been described to be as high as 6.9%. The current Consensus-Guidelines therefore recommend a structural life-time follow-up. In contrast, in 2015 the American Gastroenterological Association (AGA) explicitly states that follow-up is not recommended for resected benign IPMN. Currently, a general and international consensus is lacking. LESSONS: The presented case demonstrates that even more than 5 years following resection of benign IPMN, pancreatic cancer can occur in a separate location of the pancreatic gland. We believe that IPMNs can be considered as indicator lesions for pancreatic cancer. Patients with resected side-branch IPMN should therefore undergo long term follow-up.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso
Carcinoma Ductal Pancreático
Carcinoma Papilar
Efeitos Adversos de Longa Duração/diagnóstico
Pancreatectomia/métodos
Neoplasias Pancreáticas
[Mh] Termos MeSH secundário: Adenocarcinoma Mucinoso/patologia
Adenocarcinoma Mucinoso/fisiopatologia
Adenocarcinoma Mucinoso/cirurgia
Assistência ao Convalescente/métodos
Idoso
Carcinoma Ductal Pancreático/patologia
Carcinoma Ductal Pancreático/fisiopatologia
Carcinoma Ductal Pancreático/cirurgia
Carcinoma Papilar/patologia
Carcinoma Papilar/fisiopatologia
Carcinoma Papilar/cirurgia
Alemanha
Seres Humanos
Masculino
Gradação de Tumores
Estadiamento de Neoplasias
Pâncreas/diagnóstico por imagem
Pâncreas/patologia
Neoplasias Pancreáticas/patologia
Neoplasias Pancreáticas/fisiopatologia
Neoplasias Pancreáticas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009894


  5 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29247577
[Au] Autor:Ugai T; Kelemen LE; Mizuno M; Ong JS; Webb PM; Chenevix-Trench G; Wicklund KG; Doherty JA; Rossing MA; Thompson PJ; Wilkens LR; Carney ME; Goodman MT; Schildkraut JM; Berchuck A; Cramer DW; Terry KL; Cai H; Shu XO; Gao YT; Xiang YB; Van Den Berg D; Pike MC; Wu AH; Pearce CL; Matsuo K; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium
[Ad] Endereço:Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan.
[Ti] Título:Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium.
[So] Source:Cancer Sci;109(2):435-445, 2018 Feb.
[Is] ISSN:1349-7006
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The aldehyde dehydrogenase 2 (ALDH2) polymorphism rs671 (Glu504Lys) causes ALDH2 inactivation and adverse acetaldehyde exposure among Asians, but little is known of the association between alcohol consumption and rs671 and ovarian cancer (OvCa) in Asians. We conducted a pooled analysis of Asian ancestry participants in the Ovarian Cancer Association Consortium. We included seven case-control studies and one cohort study comprising 460 invasive OvCa cases, 37 borderline mucinous OvCa and 1274 controls of Asian descent with information on recent alcohol consumption. Pooled odds ratios (OR) with 95% confidence intervals (CI) for OvCa risk associated with alcohol consumption, rs671 and their interaction were estimated using logistic regression models adjusted for potential confounders. No significant association was observed for daily alcohol intake with invasive OvCa (OR comparing any consumption to none = 0.83; 95% CI = 0.58-1.18) or with individual histotypes. A significant decreased risk was seen for carriers of one or both Lys alleles of rs671 for invasive mucinous OvCa (OR = 0.44; 95% CI = 0.20-0.97) and for invasive and borderline mucinous tumors combined (OR = 0.48; 95% CI = 0.26-0.89). No significant interaction was observed between alcohol consumption and rs671 genotypes. In conclusion, self-reported alcohol consumption at the quantities estimated was not associated with OvCa risk among Asians. Because the rs671 Lys allele causes ALDH2 inactivation leading to increased acetaldehyde exposure, the observed inverse genetic association with mucinous ovarian cancer is inferred to mean that alcohol intake may be a risk factor for this histotype. This association will require replication in a larger sample.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/genética
Consumo de Bebidas Alcoólicas/genética
Aldeído-Desidrogenase Mitocondrial/genética
Grupo com Ancestrais do Continente Asiático/genética
Neoplasias Ovarianas/genética
Polimorfismo de Nucleotídeo Único
[Mh] Termos MeSH secundário: Estudos de Coortes
Feminino
Estudos de Associação Genética
Predisposição Genética para Doença
Seres Humanos
Modelos Logísticos
Razão de Chances
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 1.2.1.3 (ALDH2 protein, human); EC 1.2.1.3 (Aldehyde Dehydrogenase, Mitochondrial)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1111/cas.13470


  6 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374695
[Au] Autor:Matuura H; Miyamoto M; Takano M; Soyama H; Aoyama T; Yoshikawa T; Kato K; Sakamoto T; Kuwahara M; Takasaki K; Ishibashi H; Iwahashi H; Tsuda H; Furuya K
[Ad] Endereço:Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan.
[Ti] Título:Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
[So] Source:Anticancer Res;38(2):717-722, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To determine whether CD44, which is associated with tumor growth and metastasis, is related to carcinogenesis and prognosis in ovarian mucinous carcinomas (MACs). MATERIALS AND METHODS: Tissue blocks from 71 patients with benign mucinous ovarian tumors were used in the study: 35 were from patients with borderline mucinous ovarian tumors, and 60 from patients with MACs. Immunochemical analysis was performed to evaluate the expression of CD44 and examine its association with tumorigenesis and survival. RESULTS: Compared to benign tumors, borderline tumors had high CD44 expression levels (p=0.047). Conversely, MACs had lower expression than borderline tumors (p=0.032). Progression-free and overall survival of patients with MAC with low CD44 expression were worse than those of patients with high expression (p=0.04 and p=0.02, respectively). CONCLUSION: Malignant transformation of mucinous tumors is associated with changes in CD44 expression, with low expression level being a prognostic factor in MAC.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/metabolismo
Adenocarcinoma Mucinoso/mortalidade
Receptores de Hialuronatos/metabolismo
Neoplasias Ovarianas/metabolismo
Neoplasias Ovarianas/mortalidade
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/metabolismo
Feminino
Seres Humanos
Meia-Idade
Análise Multivariada
Prognóstico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CD44 protein, human); 0 (Hyaluronan Receptors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  7 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374745
[Au] Autor:Luczynska E; Niemiec J; Heinze S; Adamczyk A; Ambicka A; Marcyniuk P; Rudnicki W; Mitus JW; Dyczek S; Rys J; Sas-Korczynska B
[Ad] Endereço:Department of Radiology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Cracow, Poland.
[Ti] Título:Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
[So] Source:Anticancer Res;38(2):1085-1095, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: It is possible that the degree of enhancement on contrast-enhanced spectral mammography (CESM), a new diagnostic method, might provide prognostic information for breast cancer patients. Therefore, in a group of 82 breast cancer patients, we analyzed the prognostic significance of degree and pattern of enhancement on CESM as well as its relation to: (a) breast cancer immunophenotype (based on ER/PR/HER2 status) (b) podoplanin expression in cancer stroma (lymphatic vessel density plus podoplanin-positivity of cancer-associated fibroblasts), and (c) other histological parameters. MATERIALS AND METHODS: For each tumor the intensity of enhancement on CESM was qualitatively assessed as strong or weak/medium, while the pattern - as homogenous and heterogenous. RESULTS: Herein we report, for the first time, that strong and heterogenous enhancement on CESM was related to unfavorable disease-free survival of breast cancer patients (p=0.005). Moreover, the strong enhancement was more frequent in large and node-positive tumors (pT>1, pN>0) (p=0.002), as well as in carcinomas with podoplanin-sparse stroma (p=0.008). CONCLUSION: Intensity and pattern of enhancement on CESM might provide (together with the results of other diagnostic imaging methods) not only the confirmation of presence or absence of tumor, but also prognostic information.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/patologia
Meios de Contraste
Imagem por Ressonância Magnética/métodos
Glicoproteínas de Membrana/metabolismo
Células Estromais/metabolismo
[Mh] Termos MeSH secundário: Adenocarcinoma Mucinoso/metabolismo
Adenocarcinoma Mucinoso/patologia
Adenocarcinoma Mucinoso/terapia
Neoplasias da Mama/metabolismo
Neoplasias da Mama/terapia
Fibroblastos Associados a Câncer
Carcinoma Ductal de Mama/metabolismo
Carcinoma Ductal de Mama/patologia
Carcinoma Ductal de Mama/terapia
Carcinoma Lobular/metabolismo
Carcinoma Lobular/patologia
Carcinoma Lobular/terapia
Carcinoma Papilar/metabolismo
Carcinoma Papilar/patologia
Carcinoma Papilar/terapia
Terapia Combinada
Feminino
Seguimentos
Seres Humanos
Mamografia
Meia-Idade
Prognóstico
Estudos Retrospectivos
Células Estromais/patologia
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Contrast Media); 0 (Membrane Glycoproteins); 0 (PDPN protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  8 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374732
[Au] Autor:Shinagawa T; Hata K; Morikawa T; Takiyama H; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Nakamura H; Fukayama M; Watanabe T
[Ad] Endereço:Department of Surgical Oncology, the University of Tokyo, Tokyo, Japan takahide124@gmail.com.
[Ti] Título:Protrusion on the Depressed Surface of Non-polypoid T1 Colorectal Cancer Is Associated with Venous Invasion.
[So] Source:Anticancer Res;38(2):993-1002, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: The treatment strategies for T1 colorectal cancer (CRC) include both surgical and endoscopic resection. Surgical resection is indicated if lymphovascular invasion is present; however, the endoscopic prediction of lymphovascular invasion has not been reported. We aimed to correlate endoscopic morphology with pathological findings, including lymphovascular invasion, in non-polypoid T1 CRC. MATERIALS AND METHODS: We retrospectively investigated 63 patients with non-polypoid T1 CRC surgically resected between 2008 and 2016. Four typical endoscopic findings related to deep submucosal invasion, namely protrusion from a depressed surface, fold convergence, fullness and hardness, were assessed to elucidate their association with pathological findings. RESULTS: Protrusion was the only finding significantly correlated with positive venous invasion (67.9% of the lesions with protrusion vs. 34.3% of those without protrusion, p=0.01), which was also confirmed by a multivariable analysis (odds ratio(OR)=3.72, 95% confidence interval(CI)=1.24-11.2, p=0.02). CONCLUSION: The endoscopic finding of protrusion on a depressed surface may be a sign indicating venous invasion in non-polypoid T1 CRC.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/secundário
Adenocarcinoma/secundário
Carcinoma de Células em Anel de Sinete/secundário
Neoplasias Colorretais/patologia
Veias/patologia
[Mh] Termos MeSH secundário: Idoso
Colonoscopia
Feminino
Seguimentos
Seres Humanos
Metástase Linfática
Masculino
Invasividade Neoplásica
Prognóstico
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  9 / 8555 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374722
[Au] Autor:Kalampokas E; Young H; Bednarek A; Habib M; Parkin DE; Gurumurthy M; Cairns M
[Ad] Endereço:Department of Gynecologic Oncology, Aberdeen Royal Infirmary, Aberdeen, U.K. m.kalampokas@gmail.com.
[Ti] Título:Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre.
[So] Source:Anticancer Res;38(2):923-928, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Ovarian cancer (OC) has a high mortality rate and usually presents late in advanced stage, which poses challenges to management. Better understanding of the disease biology and application of radical surgery (RS) to achieve no visible residual tumor, alongside with chemotherapy, may lead to longer survival amongst these patients. Our purpose was to examine the demographic characteristics, surgical morbidity and outcomes of patients undergoing RS for OC. MATERIALS AND METHODS: A retrospective cohort study of women undertaking surgery for OC between February 2014 and September 2016 in Aberdeen Royal Infirmary. RESULTS: A total of 121 women had surgery for OC of whom 78 (64.5%) were stage II and above. Of these, 40 (51.3%) women had primary and 38 (48.7%) had interval debulking surgery with 42 (53.8%) having radical surgery. The most common procedures that were performed as part of RS included rectosigmoid resection (n=20, 47.6%), small bowel resection (n=10, 23.8%), splenectomy (n=9, 21.4%). Morbidity outcomes included blood loss >1.5 lt. (n=14, 33.3%), hospitalization >7days (n=31, 73.8%), sepsis (n=8, 19%). There was no short-term mortality. Debulking outcomes were: no macroscopic residual disease (n=36, 85.7%), ≤10 mm disease (n=2, 4.8%), and ≥10 mm disease (n=3, 7.1%). CONCLUSION: Our findings support the practise where RS for OC can be offered to selected patients, with good surgery outcomes and low morbidity rates.
[Mh] Termos MeSH primário: Adenocarcinoma de Células Claras/cirurgia
Adenocarcinoma Mucinoso/cirurgia
Cistadenocarcinoma Seroso/cirurgia
Neoplasias do Endométrio/cirurgia
Neoplasias Ovarianas/cirurgia
[Mh] Termos MeSH secundário: Adenocarcinoma de Células Claras/patologia
Adenocarcinoma Mucinoso/patologia
Idoso
Cistadenocarcinoma Seroso/patologia
Procedimentos Cirúrgicos de Citorredução
Neoplasias do Endométrio/patologia
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Morbidade
Neoplasias Ovarianas/patologia
Estudos Retrospectivos
Escócia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  10 / 8555 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28921520
[Au] Autor:Jung S; Allen N; Arslan AA; Baglietto L; Barricarte A; Brinton LA; Egleston BL; Falk RT; Fortner RT; Helzlsouer KJ; Gao Y; Idahl A; Kaaks R; Krogh V; Merritt MA; Lundin E; Onland-Moret NC; Rinaldi S; Schock H; Shu XO; Sluss PM; Staats PN; Sacerdote C; Travis RC; Tjønneland A; Trichopoulou A; Tworoger SS; Visvanathan K; Weiderpass E; Zeleniuch-Jacquotte A; Dorgan JF
[Ad] Endereço:Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD.
[Ti] Título:Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
[So] Source:Int J Cancer;142(2):262-270, 2018 Jan 15.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (P : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all P : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all P : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.
[Mh] Termos MeSH primário: Adenocarcinoma de Células Claras/etiologia
Adenocarcinoma Mucinoso/etiologia
Biomarcadores/sangue
Cistadenocarcinoma Seroso/etiologia
Neoplasias do Endométrio/etiologia
Neoplasias Ovarianas/etiologia
[Mh] Termos MeSH secundário: Adenocarcinoma de Células Claras/sangue
Adenocarcinoma de Células Claras/epidemiologia
Adenocarcinoma Mucinoso/sangue
Adenocarcinoma Mucinoso/epidemiologia
Adulto
Hormônio Antimülleriano/sangue
Estudos de Casos e Controles
Estudos de Coortes
Cistadenocarcinoma Seroso/sangue
Cistadenocarcinoma Seroso/epidemiologia
Neoplasias do Endométrio/sangue
Neoplasias do Endométrio/epidemiologia
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Gradação de Tumores
Estadiamento de Neoplasias
Neoplasias Ovarianas/sangue
Neoplasias Ovarianas/epidemiologia
Pré-Menopausa
Prognóstico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 80497-65-0 (Anti-Mullerian Hormone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170919
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.31058



página 1 de 856 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde